ARA320823 is an experimental peptide derived from erythropoietin that is being investigated for its tissue protective and anti inflammatory properties without stimulating red blood cell production. Developed under Araim Pharmaceuticals’ non hematopoietic erythropoietin mimetic program, it is intended to retain the cytoprotective and immune modulating effects of erythropoietin while avoiding its role in increasing hemoglobin levels. Preclinical research suggests ARA320823 may help reduce inflammatory signaling, protect cells from oxidative and ischemic damage, and support tissue repair processes, with the potential to minimize risks such as elevated hemoglobin or thrombosis associated with conventional erythropoietin therapies.